Stada Says Teriparatide Roll-Out Has Been Successful

German Firm Launched In European Markets In August Last Year

Seven months after introducing its teriparatide biosimilar to Eli Lily’s Forsteo into many European markets, Stada is pleased with results and says doctors and patients alike have responded well.

Consultation
Doctors and patients have responded well, Stada says • Source: Shutterstock

Stada has described the launch of its Movymia (teriparatide) biosimilar in EU markets as a “success” and says doctors and patients alike have “reacted very positively” to the product’s reusable applicator pen.

Having in-licensed the biosimilar osteoporosis therapy from fellow European heavyweight Gedeon Richter, Stada introduced Movymia upon patent expiry in late...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.